No Data
Zhejiang Cheng Yi Pharmaceutical (603811.SH): The marine biomedical manufacturing project has been completed in this period
Gelonghui 18th November | Zhejiang Cheng Yi Pharmaceutical (603811.SH) stated at the performance briefing that the marine biomedical manufacturing project has been completed in this period. The company is advancing the construction of the "Two Strong and One Major Project", including high-purity fish oil, in accordance with the requirements of being the largest in Asia, with the lowest cost and the best quality. With the gradual expansion of the market, the future of the high-purity fish oil market looks promising.
Why Zhejiang Cheng Yi Pharmaceutical's (SHSE:603811) Shaky Earnings Are Just The Beginning Of Its Problems
Sincerity Pharmaceutical (603811.SH): Obtaining stock repurchase loans from financial institutions
On November 7, Ge Longhui Pharmaceutical (603811.SH) announced that recently, in accordance with the “Notice Concerning Matters Relating to Establishing Stock Repurchase and Increase Refinancing” issued by the People's Bank of China, the Financial Supervisory Authority, and the China Securities Regulatory Commission, a stock repurchase increase reloan has been established to encourage and guide financial institutions to provide loans to eligible listed companies and major shareholders to support them to repurchase and increase their holdings of listed companies' shares. Following an agreement between the company and the branch office of China Construction Bank Co., Ltd., China Construction Bank Co., Ltd. authorized the branch to issue the “China Construction Bank Loan Commitment” and agreed to provide shares to the company
Chengyi Pharmaceutical: Zhejiang Chengyi Pharmaceutical Co., Ltd. Report for the Third Quarter of 2024
Zhejiang Chengyi Pharmaceutical Co., Ltd. Report for the Third Quarter of 2024
Announcement of Zhejiang Chengyi Pharmaceutical Co., Ltd. on the main operating data for the third quarter of 2024
Benign Growth For Zhejiang Cheng Yi Pharmaceutical Co., Ltd. (SHSE:603811) Underpins Stock's 28% Plummet
